Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Controlled release of multiple epidermal induction factors through core-shell nanofibers for skin regeneration.

Jin G., Prabhakaran MP., Kai D., Ramakrishna S.

Laboratory Study on Chronic Wound, published in Eur J Pharm Biopharm (2013) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Eur J Pharm Biopharm (2013)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
23791682
DOI
10.1016/j.ejpb.2013.06.002
Citations
65

Abstract (original English)

With advances in the field of tissue engineering, it is increasingly recognized that biodegradable and biocompatible scaffolds incorporated with multiple wound healing mediators might serve as the most promising medical devices for skin tissue regeneration. Through controlled drug delivery, these medical devices can reduce the toxicity effects and optimize clinical efficiency. In this study, we first encapsulated multiple epidermal induction factors (EIF) such as the epidermal growth factor (EGF), insulin, hydrocortisone, and retinoic acid (RA) with gelatin and poly(L-lactic acid)-co-poly-(ε-caprolactone) (PLLCL) solutions and performed electrospinning by two different approaches: blend spinning and core-shell spinning. No burst release was detected from EIF encapsulated core-shell nanofibers; however, an initial 44.9% burst release from EIF blended nanofibers was observed over a period of 15 days. The epidermal differentiation potential of adipose-derived stem cells (ADSCs) was evaluated for EIF-containing scaffolds prepared either by core-shell spinning or by blend spinning. After 15 days of cell culture, the proliferation of ADSCs on EIF encapsulated core-shell nanofibers was the highest. Moreover, a higher percentage of ADSCs got differentiated to epidermal lineages on EIF encapsulated core-shell nanofibers compared to the cell differentiation on EIF blended nanofibers, whi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueCell DifferentiationCell ProliferationDelayed-Action PreparationsDrug Delivery SystemsEpidermal Growth FactorGelatinHumansHydrocortisoneInsulin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research